<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115607</url>
  </required_header>
  <id_info>
    <org_study_id>W81XWH-12-1-0066</org_study_id>
    <nct_id>NCT02115607</nct_id>
  </id_info>
  <brief_title>Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy</brief_title>
  <official_title>Quantitative Subharmonic Breast Imaging: Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a diagnostic accuracy study to evaluate if two novel ultrasound (US) techniques,
      quantitative 3D subharmonic imaging (SHI) and Subharmonic Aided Pressure Estimation (SHAPE),
      used with an intravenous ultrasound contrast agent (Definity, Lantheus Medical Imaging,
      Billerica, MA), can track changes in locally advanced breast cancer (LABC) angiogenesis and
      interstitial fluid pressure (IFP), respectively, by studying women undergoing neoadjuvant
      chemotherapy before as well as with around 10% and 60% (in part 1) or 30% (in part 2) of the
      neoadjuvant chemotherapy treatment delivered and after completion of the neoadjuvant
      chemotherapy treatment. Results will be compared to MRI and pathology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in biomarker assessment over treatment period</measure>
    <time_frame>Neoadjuvant chemotherapy treatment period; on average 6 months</time_frame>
    <description>To evaluate the ability of 3D SHI and SHAPE, used with Definity, to track changes in LABC angiogenesis and IFP, respectively, by studying women undergoing neoadjuvant chemotherapy before as well as with around 10% and 60% (in part 1) or 30% (in part 2) of the neoadjuvant chemotherapy treatment delivered and after completion of the neoadjuvant chemotherapy treatment and comparing results to MRI and pathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SHI depiction of breast cancer angiogenesis</measure>
    <time_frame>After surgery; on average 6 months</time_frame>
    <description>To compare the 3D SHI depiction of breast cancer angiogenesis in humans to CD31, an immunohistochemical predictor of angiogenesis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Definity infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of Definity (Perflutren Lipid Microspheres)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Definity infusion</intervention_name>
    <description>3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min</description>
    <arm_group_label>Definity infusion</arm_group_label>
    <other_name>Perflutren Lipid Microspheres</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females

          -  Be diagnosed with T1 or greater LABC, any N and M0.

          -  Be scheduled for neoadjuvant chemotherapy

          -  Be at least 21 years of age.

          -  Be medically stable.

          -  If a female of child-bearing potential, must have a negative pregnancy test.

          -  Have signed Informed Consent to participate in the study.

        Exclusion Criteria:

          -  Males

          -  Females who are pregnant or nursing.

          -  Patients with other primary cancers requiring systemic treatment.

          -  Patients with any metastatic disease.

          -  Patients undergoing neoadjuvant endocrine therapy.

          -  Patients with known hypersensitivity or allergy to any component of Definity.

          -  Patients with cardiac shunts or congenital heart defects.

          -  Patients with unstable cardiopulmonary conditions or respiratory distress syndrome.

          -  Patients with uncontrollable emphysema, pulmonary vasculitis, pulmonary hypertension
             or a history of pulmonary emboli.

          -  Patients who have received any contrast medium (X-ray, MRI, CT or US) in the 24 hours
             prior to the research US exam.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flemming Forsberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Flemming Forsberg, PhD</last_name>
    <phone>215-955-4870</phone>
    <email>flemming.forsberg@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flemming Forsberg, PhD</last_name>
      <phone>215-955-4870</phone>
      <email>flemming.forsberg@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Annina Wilkes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Sevrukov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Simone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Jaslow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Interstitial fluid pressure</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Contrast enhanced ultrasound imaging</keyword>
  <keyword>Subharmonic imaging</keyword>
  <keyword>Subharmonic pressure estimation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

